

CURRICULUM VITAE

Personal Data

Name: Jan Trøst Jørgensen

Address: Baunevænget 76
Nødebo
DK-3480 Fredensborg
Denmark

Tel: +45 4848 0528
Mob: +45 4074 7846
E-mail: jan.trost@dx-rx.dk



Present Employment: Director of Medical Affairs
CMC Contrast AB
Scion DTU
Diplomvej 376,1
DK-2800 Lyngby
Denmark

Tel: +45 8870 8990
Fax: +45 8870 8090
E-mail: jtj@cmc-contrast.se

Education and Qualifications

1973 - 1976 General Certificate of Education A-level,
Odense Katedralskole

1976 - 1983 M.Sc.Pharm.
The University of Pharmaceutical Sciences, Copenhagen

1990 - 1992 Ph.D., The University of Pharmaceutical Sciences, Copenhagen
Title of thesis: Self-administration of Growth Hormone and
Insulin. Efficacy and Patient Acceptance.

(For postgraduate education see attached list).

Work Experience

- 1979 - 1981 Pharmacy Assistant (Substitute)
Aarup Pharmacy, Aarup, Denmark
- 1981 - 1983 Research Assistant
Finsen Laboratory
Finsens Hospital, Copenhagen, Denmark
Responsibilities: Basic research within oncology.
- 1983 - 1986 Medical Sponsor
Medical Department
Ciba-Geigy A/S, Copenhagen, Denmark
Responsibilities: Regulatory affaires and clinical development (phase II-IV) within oncology, rheumatology and CNS.
- 1986 - 1989 Head of Clinical Research
Clinical Research Department
Nordisk Gentofte A/S, Copenhagen, Denmark
Responsibilities: Clinical development (phase I-IV) within diabetes and growth disorders.
- 1989 - 1994 Director
Medical Department Growth Factors
Biopharmaceutical Division, Novo Nordisk A/S, Copenhagen, Denmark
Responsibilities: Clinical development (phase I-IV) within growth disorders and adult growth hormone deficiency. Member of the R&D Management.
- 1994 - 1996 Head of Nordic Cancer Care Unit
Ciba Cancer Care
Ciba-Geigy A/S /Novartis A/S, Copenhagen, Denmark
Responsibilities: Clinical development (phase III-IV) within oncology in the Nordic countries. Member of the Management of Novartis A/S.
- 1996 - 1998 Clinical Research Manager
International Marketing/ International Clinical Development,
Nycomed Pharma A/S, Roskilde, Denmark
Responsibilities: Clinical development (phase III-IV) and marketing support within pain management and rheumatology.
- 1998 – 2000 Vice President
Research and Development and Clinical Development
Pronosco A/S, Vedbæk, Denmark
Responsibility: Research and development, regulatory affairs and clinical development within diagnostics for osteoporoses and rheumatology. Member of the Management of Pronosco A/S.

- 2000 - 2001 Director
Clinical Development
Pharmexa A/S, Hørsholm, Denmark
Responsibilities: Clinical development (phase I/II) within oncology and immunology. Member of the R&D Management.
- 2001 - 2004 Vice President
Research and Development
T-cellic A/S, Hørsholm, Denmark
Responsibilities: Research and development, regulatory affairs and clinical development (phase I/II) within oncology drug/diagnostic combinations. Member of the Management of T-cellic A/S.
- 2004 -2008 Senior Principal Scientist
Global Science/ Clinical Affairs
Dako Denmark A/S, Glostrup, Denmark
Responsibilities: Research and development and clinical development within oncology/molecular diagnostics. Member of the Global R&D Management.

Postgraduate Education

- 1983 Oncology (2 days).
MEDIF/ MEFA, Copenhagen.
- 1984 Controlled Therapeutic Studies (1 day).
MEDIF/ MEFA, Copenhagen.
- Medical Research Methodology (6 days).
Danish Medical Association, Copenhagen.
- 1985 Computer Science (1 year).
HF-course, Copenhagen.
- Psychiatry and Neurobiology (5 days).
University Hospital of Copenhagen.
- Immunology (3 days). MEDIF/ MEFA, Copenhagen.
- 1986 Physiology (1 year).
The Royal Danish School of Pharmacy, Copenhagen.
- Pathology (5 months).
The Royal Danish School of Pharmacy, Copenhagen
- The Controlled Clinical Trial (2 days).
The Danish Society of Clinical Pharmacology, Copenhagen.
- Statistical Analysis (2 days).
University of Copenhagen
- 1987 The Clinical Research Project (3 days).
The Swedish Pharmaceutical Association, Gothenburg.
- How to Perform Clinical Trials to US GCP (2 days)
IBC-Legal Studies and Services Ltd., London.
- Good Clinical Practice (2 days).
Medical and Clinical Research Consultants Ltd., London
- 1989 Good Clinical Practice in Europe (2 days).
IBC-Legal Studies and Services Ltd., Copenhagen.
- 1990 Business Economy (1 year).
Niels Brock, Copenhagen Business College.
- Wound Management: Varicose Ulcers (2 days).
Medical and Clinical Management Ltd., London.

- The Personal Resources of the Manager (3 days).
Novo Nordisk Management Education.
Novo Nordisk, Bagsværd.
- Visions and Management (3 days).
Novo Nordisk Management Education.
Novo Nordisk, Bagsværd.
- 1992 Ph.D. thesis: Self-administration of Growth Hormone and Insulin. Efficacy and Patient Acceptance. The Royal Danish School of Pharmacy, Copenhagen.
- 1994 Treatment of Cancer (5 days).
Department of Oncology, University Hospital of Copenhagen.
- Negotiation Training Course (3 days).
Ciba Marketing Development, Ciba-Geigy, Copenhagen
- Interpretation of Clinical Biochemistry Data (2 days).
Pharmaceutical Postgraduate Education, Copenhagen
- 1995 Marketing (1 year).
Niels Brock, Copenhagen Business College.
- TQM (Total Quality Management) (2 days).
Ciba Education Program, Ciba-Geigy, Copenhagen
- 1996 Basic Clinical Work (3 days).
University Hospital of Copenhagen.
Postgraduate Education in Clinical Pharmacy, The Danish Society of Clinical Pharmacy.
- Health Economy (1 day).
MEDIF/MEFA, Copenhagen.
- Refresher Courses:
Acute Pain Management (½ day)
Design of Clinical Trials of Pain Treatment (½ day)
8th World Congress on Pain, Vancouver, Canada, August 17-22.
- Treatment of Pain (3 days)
MEDIF/ MEFA, Copenhagen.
- Oncology (3 days).
Department of Oncology, Aalborg Country Hospital South.
Postgraduate Education in Clinical Pharmacy, The Danish Society of Clinical Pharmacy.
- 1997 Treatment of Pain (3 days).
Department of Anesthesiology, Odense University Hospital.

- Postgraduate Education in Clinical Pharmacy, The Danish Society of Clinical Pharmacy.
- 1998 Rheumatology (3 days).
Department of Rheumatology, Frederiksberg Hospital.
Postgraduate Education in Clinical Pharmacy, The Danish Society of Clinical Pharmacy.
- 1999 DXA Course (1 day)
Synarc, Copenhagen
- 2000 Impact of New Therapeutics in Osteoporosis (3 days)
ISCD Medical Education Meeting, Tempe, Arizona
International Society of Clinical Densitometry
- 2001 Good Clinical Practice (1 day)
The Danish Society of Good Clinical Practice, Copenhagen
- 2004 Infectious Diseases (3 days)
Department of Infectious Diseases, Odense University Hospital.
Postgraduate Education in Clinical Pharmacy, The Danish Society of Clinical Pharmacy.
- Principles of Molecular Oncology (½ day)
Educational Symposia, ASCO, New Orleans, LA, USA
- 2005 HPV testing and Management in Cervical Cancer (2 days)
Clinical Workshop, 22nd International Papillomavirus and Conference,
Vancouver, BC, Canada
- Clinical Drug Development: Oncology (2½ day)
Drug Information Association, Baltimore, MD, USA
- 2006 New Applications of Molecular Epidemiology in Cancer (½ day)
Educational Symposia, ASCO, Atlanta, GA, USA
- 2007 Preparing for an FDA Advisory Committee Meeting
Webcast arranged by Regulatory Affairs Professionals Society, USA
- Statistical Analysis with SPSS I (2 days).
SPSS A/S, Holte, Denmark
- Statistical Analysis with SPSS II (2 days).
SPSS A/S, Holte, Denmark

In addition to above courses, I have participated in several internal courses in GCP and EDP during my employment with Pharmexa, Nycomed Pharma, Novartis and Novo Nordisk.

Scientific Publications

1. Jørgensen JOL, Flyvbjerg A, Jørgensen JT, Sørensen HH, Johansen BR, Christiansen JS. NPH Insulin Administration by Means of an Injection Pen. *Diabetic Med.* 1988, 5: 441-443.
2. Jørgensen JOL, Møller J, Jensen FS, Jørgensen JT, Christiansen JS: Growth Hormone Administration by Means of an Injection Pen. *Pharmacol Toxicol* 1989, 65: 96-99.
3. Jørgensen JT, Mortensen HB, Jørgensen JOL. Patient Acceptance of Nordiject. A New Drug Delivery System for Growth Hormone. *DICP Ann Pharmacother* 1991, 25: 585-588.
4. Mortensen HB, Main K, Michaelsen KF, Kastrup KW, Jørgensen JT, Skakkebæk NE. Prediction and Monitoring of Growth in Children with Short Stature during the First Year of Growth Hormone Treatment. *Acta Paediatr Scand* 1991, 80: 1150-1157.
5. Jørgensen JT, Christensen T, Jørgensen M, Jakobsen G. Development, Production and Pharmacodynamics of Human Growth Hormone. *Indian J Pediatr* 1991, 58 (Suppl): 23-32.
6. Jørgensen JT, Susgaard S. Growth Hormone Therapy with a New Delivery System. *Indian J Pediatr* 1991, 58 (Suppl): 43-50.
7. Jørgensen JT, Mortensen HB, Jørgensen JOL, Jakobsen G: Acceptability of Nordiject. A New Drug Delivery System for Growth Hormone. In: *Optimising Clinical Pharmacy Practice*. Müller NF, Lacasa C, Sado PA and Walker R eds. Amsterdam Medical Press B.V., 1991: 79-80.
8. Jørgensen JT. Self-administration of Growth Hormone and Insulin. Efficacy and Patient Acceptance. *Lægeforeningens Forlag, Copenhagen, September 1992. (Ph.D. thesis)*
9. Mortensen HB, Main K, Michaelsen KF, Kastrup KW, Jørgensen JT, Skakkebæk NE. Evaluering af knemometri som metode til monitorering af højdetilvækst hos væksthæmmede børn under et års væksthormonbehandling. *Ugeskr læger* 1993, 155: 1135-1139.
10. Jørgensen JT. Improvement of Patient Convenience in Treatment with Growth Hormone. *J Pediatr Endocrinol* 1994, 7: 175-180.
11. Main K, Jørgensen JT, Hertel T, Jensen S, Jakobsen L. Automatic Needle Insertion Diminishes Pain during Growth Hormone Injection. *Acta Paediatr Scand* 1995, 84: 331-334.
12. Jørgensen JT, Rømsing J, Rasmussen M, Møller-Sonnergaard J, Vang L, Musæus L. Pain Assessment of Subcutaneous Injections. *Ann Pharmacother* 1996; 30: 729-732.
13. Jørgensen JT, Rasmussen M, Rømsing J. Is the Pain of a Subcutaneous Injection Related to the injection volume? *Dolor* 1997; 12 (Suppl): 33.

14. Rasmussen M, Jørgensen JT, Rømsing J. Patient Acceptability of Two Different Brands of Nicotine Chewing Gum. *Clin Drug Invest* 1997; 13: 277-281.
15. Jørgensen JT, Andersen PB, Rosholm A, Bjarnason NH. Digital X-ray Radiogrammetry: A New Appendicular Bone Densitometric Method with High Precision. *Clin Phys* 2000; 5: 330-335. (<http://www.interscience.wiley.com/journal/120099383/abstract>)
16. Hyldstrup L, Jørgensen JT, Sørensen TK, Bæksgaard L. Response of Cortical Bone to antiresorptive treatment. *Calcif Tissue Int* 2001; 68: 135-139.
17. Black DM, Palermo L, Sørensen T, Jørgensen JT, Lewis C, Tylavsky F, Wallace R, Harris E, Cummings SR. A Normative Reference Database Study for the Pronosco X-poseure Radiogrammetry System. *J Clin Densitom* 2001; 4: 5-12.
18. Gundersen HJ, Hansen SB, Gjedde A, Jørgensen HS, Marqversen J, Agger R, Andersen TE, Fleischer C, Petersen MS, Hokland M, Hulgaard E, Jørgensen JT, Skands U. A Methodology for Quantifying and Visualizing Cell homing/Accumulation by Combined Positron Emission Tomography and Magnetic Resonance Imaging. *Medical Imaging 2004: Physiology, Function, and Structure from Medical Images 2004*; 5369: 361-370.
19. Agger R, Petersen MS, Fleischer C, Hansen SB, Jørgensen HS, Skands U, Blankenstein T, Andersen TE, Hulgaard E, Jørgensen JT, Marqversen J, Gundersen HJ, Hokland M. T cell homing to tumors detected by 3D-coordinated positron emission tomography and magnetic resonance imaging. *J Immunother* 2007; 30: 29-39. (<http://www.immunotherapy-journal.com/pt/re/jimmuno/abstract.00002371-200701000-00003.htm>)
20. Jørgensen JT, Nielsen KV, Ejlertsen B. Pharmacodiagnosics and Targeted Therapies – A rational approach for individualizing medical anti-cancer therapy in breast cancer. *Oncologist* 2007; 12:397-405. ***Selected for Continuing Medical Education (CME) accreditation in the US.*** (<http://theoncologist.alphamedpress.org/cgi/content/abstract/12/4/397>)
21. Nielsen KV, Jørgensen JT, Schønau A, Øster A. Human epidermal growth factor receptor 2 testing in breast cancer. *Arch Pathol Lab Med.* 2007; 131: 1330.
22. Nielsen KV, Jørgensen JT, Schønau A, Øster A. Human epidermal growth factor receptor 2 testing in breast cancer. *J Clin Oncol.* 2007; 25: 4020.
23. Jørgensen JT. From blockbuster medicine to personalized medicine. *Personalized Medicine* 2008. 5: 55-63. (<http://www.futuremedicine.com/doi/abs/10.2217/17410541.5.1.55>)
24. Nielsen KV, Ejlertsen B, Møller S, Jørgensen JT, Knoop A, Jørgensen HK, Mouridsen H. The value of *TOP2A* gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. *Acta Oncol.* 2008; 47: 725-734. (<http://www.informaworld.com/smpp/content~db=all?content=10.1080/02841860801995396>)

25. Jensen SA, Vainer B, Witton CJ, Jørgensen JT, Sørensen JB. Prognostic significance of numeric aberrations of genes for Thymidylate synthase, Thymidine Phosphorylase and Dihydrofolate reductase in colorectal cancer. *Acta Oncol.* 2008; 47: 1054-1061. (<http://www.informaworld.com/smpp/content~db=all?content=10.1080/02841860801942158>)
26. Jørgensen JT. From blockbuster medicine to personalized medicine. *Medscape* 2008. (<http://www.medscape.com/viewarticle/573750>). Posted 05/28/2008.
27. Jørgensen JT. Are we approaching the post blockbuster era? – Pharmacodiagnosics and rational drug development. *Expert Rev Mol Diagn* 2008; 8; 689-695. (<http://www.expert-reviews.com/doi/abs/10.1586/14737159.8.6.689>)
28. Jørgensen JT. New Era of Personalized Medicine – A Ten Year Anniversary. *Oncologist* 2009; 14: 557-558. (<http://theoncologist.com/cgi/content/full/14/5/557>)
29. Jørgensen JT, Winther H. The New Era of Personalized Medicine: 10 Years Later. *Personalized Medicine* 2009; 6: 423-428. (<http://www.futuremedicine.com/doi/abs/10.2217/pme.09.24>)
30. Hoff KD, Jørgensen JT, Müller S, Rasmussen OF, Schønau A. Visualization of FISH Probes by Dual Color Chromogenic In Situ Hybridization. Accepted for publication in *American Journal of Clinical Pathology*. ***Selected for Continuing Medical Education (CME) accreditation in the US.***
31. Jørgensen JT. Targeted HER2 Treatment in Advanced Gastric Cancer. Accepted for publication in *Oncology*.

Scientific Abstracts and Presentations

1. Jørgensen JOL, Flyvbjerg A, Jørgensen JT, Sørensen HH, Johansen BR, Christiansen JS. NPH Insulin Administration by Means of an Injection Pen. An open randomized cross-over study. The 7th Workshop of the AIDSPIT Study Group, Igls, Austria. January 31 - February 2, 1988.
2. Jørgensen JOL, Flyvbjerg A, Jørgensen JT, Sørensen HH, Johansen BR, Christiansen JS. NPH Insulin administration by Means of an Injection pen. The 8th International Congress of Endocrinology, Kyoto, Japan, July 17-3, 1988.
3. Jørgensen JOL, Jørgensen JT, Sørensen HH, Kappelgaard AM, Christiansen JS. NPH Insulin Concentration in vials and Cartridges. In vivo in use test. The 8th Workshop of the AIDSPIT Study Group, Igls, Austria, January 29-31, 1989.
4. Møller J, Jørgensen JOL, Jørgensen JT, Jensen FS, Christiansen JS. Growth Hormone Administration by Means of an Injection Pen. The British Endocrine Society Meeting, York, UK, April 10-12, 1989.
5. Mortensen HB, Michaelsen KF, Skakkebak NE, Welling K, Kastrup KW, Jørgensen JT. Linear Growth and Knee-hell Measurements of GH Treatment in Children with Short Stature. The European Society for Paediatric Endocrinology, Jerusalem, Israel, October 29 - November 3, 1989.
6. Jørgensen JT, Mortensen HB, Jørgensen JOL, Jakobsen G. Acceptability of Nordiject. A New Drug Delivery System for Growth Hormone. The 19th European Symposium on Clinical Pharmacy, Barcelona, Spain, October 24-26, 1990.
7. Jørgensen JT. Development, Production and Pharmacodynamics of Human Growth Hormone. The New Delhi hGH Symposium. Recent Advances in Growth Hormone Replacement Therapy. New Delhi, India, December 1-3, 1990.
8. Jørgensen JT. B-hGH Therapy with a New Delivery System. The New Delhi hGH Symposium. Recent Advances in Growth Hormone Replacement Therapy. New Delhi, India, December 1- 3, 1990.
9. Bridges A, Stirling H, McDowell J, Jensen S, Jørgensen JT, Kelnar C. Double Blind Study to Compare the Local Tolerance of Three Different Solvents used to Reconstitute Growth Hormone. The British Pharmacological Society, London, UK, December 17-19, 1991.
10. Susgaard S, Jørgensen JT. Growth Hormone Treatment with an Injection Pen. The Nordic Endocrinology Meeting, Geilo, Norway, March 11-13, 1992.
11. Jørgensen JT, Kappelgaard AM, Johansen BR. Optimization of Patient Convenience in Relation to Growth Hormone Treatment. The 21st European Symposium on Clinical Pharmacy, Copenhagen, Denmark, October 14-7, 1992.

12. Jørgensen JT. Clinical Experiences with Nordiject. A Novel Growth Hormone Pen System. Scientific Symposium - New Aspects of Growth Hormone Therapy, Tokyo, Japan, February 13, 1993.
13. Jørgensen JT. Improvement of Patient Convenience in Treatment with Growth Hormone. Workshop on Growth No. 6, Copenhagen, Denmark, October 1-2, 1993.
14. Jørgensen JT. Administration of Growth Hormone. Scientific Meeting - New Aspects within the area of Growth Hormone. Department of Paediatric Endocrinology, Regional Hospital of Malaga. University of Malaga, Spain, January 21, 1994.
15. Jørgensen JT. Bisphosphonates - Pharmacology and Route of Administration. Mini Symposium on Bisphosphonates, Umeå, Sweden, March 27, 1996.
16. Jørgensen JT. Patient Acceptance in relation to Development of Injection Fluids. Meeting on Patient Acceptance and Drug Development. The Danish Society of Pharmacy, Copenhagen, Denmark, April 29, 1996.
17. Rasmussen M, Jørgensen JT, Rømsing J. Patient Acceptability of Nicotine Chewing Gum. The 25th European Symposium on Clinical Pharmacy, Lisbon, Portugal, October 9-11, 1996.
18. Jørgensen J T, Rømsing J, Rasmussen M. Is the Pain of a Subcutaneous Injection Related to the Injection Volume? The 5th EuroPain Conference on Pain Research, Brügge, Belgium, January 16-18, 1997.
19. Hyldstrup L, Jørgensen JT, Sørensen TK, Baeksgaard L. Bisphosphonate Treatment Evaluated by New Qualitative Measures of Cortical Bone. The American Society for Bone and Mineral Research 21st Annual Meeting, St. Louis, Missouri, USA, September 28 – October 4, 1999.
20. Jørgensen JT, Andersen PB, Rosholm A, Bjarnason NH. Digital X-ray Radiogrammetry: A New X-ray Based BMD Device with a low precision error. The American Society for Bone and Mineral Research 21st Annual Meeting, St. Louis, Missouri, USA, September 28 – October 4, 1999.
21. Andersen H, Jørgensen JT, Helboe AB, Bjarnason NH. DXR BMD has a Superior Discriminatory Ability of Patients with and without Vertebral Fractures when Compared to DXA BMD. The World Congress on Osteoporosis, Chicago, Illinois, USA, June 15-18, 2000.
22. Hyldstrup L, Sørensen TK, Baeksgaard L, Arnbjerg D, Jørgensen JT. Identification of Women at Risk of Osteoporosis: Comparison of Digital X-ray Radiogrammetry with DXA Measurements at the Spine and Hip. The World Congress on Osteoporosis, Chicago, Illinois, USA, June 15-18, 2000.
23. Hyldstrup L, Jørgensen JT, Sørensen TK, Baeksgaard L. Hormone Replacement Therapy and Bisphosphonate Treatment Evaluated by New Qualitative Measures of the Cortical one. The World Congress on Osteoporosis, Chicago, Illinois, USA, June 15-18, 2000.

24. Jørgensen JT, Andersen PB, Rosholm A, Bjarnason NH. High Short-Term Precision with Digital X-ray Radiogrammetry. The World Congress on Osteoporosis, Chicago, Illinois, USA, June 15-18, 2000.
25. Rosholm A, Arnbjerg D, Paulsen R, Thodberg HH, Jørgensen JT. Digital X-ray Radiogrammetry. The 14th International Bone Densitometry Workshop, Warnemünde, Germany, September 3-8, 2000.
26. Hyldstrup L, Sørensen TK, Jørgensen JT, Bæksgaard L. HRT and Bisphosphonate Treatment Evaluated by New Qualitative Measures of Cortical Bone. The 14th International Bone Densitometry Workshop, Warnemünde, Germany, September 3-8, 2000.
27. Hyldstrup L, Sørensen TK, Bæksgaard L, Jørgensen JT. Comparison of Digital X-ray Radiogrammetry with DXA Measurements at the Spine and Hip. The 14th International Bone Densitometry Workshop, Warnemünde, Germany, September 3-8, 2000.
28. Hyldstrup L, Sørensen TK, Bæksgaard L, Arnbjerg D, Bach-Mortensen P, Jørgensen JT. Digital X-ray Radiogrammetry: Comparison with DXA Measurements of the Spine and Hip. The American Society for Bone and Mineral Research 22nd Annual Meeting, Toronto, Ontario, Canada September 22-26, 2000.
29. Hyldstrup L, Jørgensen JT, Gaich G. Assessment of Effects of LY333334 [rhPTH(1-34)] on Cortical Bone using DXR. The 1st Joint Meeting of IBMS and ECTS. Madrid, Spain June 5-10, 2001.
30. Gundersen HJ, Hansen SB, Gjedde A, Jørgensen HS, Marqversen J, Agger R, Andersen TE, Fleischer C, Petersen MS, Hokland M, Hulgaard E, Jørgensen JT, Skands U. A Methodology for Quantifying and Visualizing Cell homing/Accumulation by Combined Positron Emission Tomography and Magnetic Resonance Imaging. SPIE Medical Imaging, San Diego, California, USA, February 14-19, 2004.
31. Petersen MS, Fleischer C, Hansen SB, Jørgensen HS, Skands U, Andersen TE, Hulgaard EF, Jørgensen JT, Marqversen J, Gundersen HJ, Hokland M, Agger R. Homing of Tumor-specific T cells in the B16-OVA/OT-I Model System - Towards T cells as Carriers of Cytotoxic Substances in Therapy of Cancer. ISBCT 19th Annual Meeting San Francisco, California, USA, November 4-7, 2004.
32. Jørgensen JT. Selection of Patients for Targeted Therapy in Breast Cancer. Invited speaker at the Oncology Clinical Trials. IIR Conference, Las Vegas, USA, April 3-5, 2006.
33. Knoop AS, Knudsen H, Balslev E, Rasmussen B, Overgaard J, Nielsen KV, Jørgensen JT, Düring M, Mouridsen H, Ejlertsen B. *TOP2A* aberrations as predictive and prognostic marker in high-risk breast cancer patients. A randomized DBCG Trial (DBCG89D). ASCO annual meeting 2006, Atlanta, USA; June 2-6, 2006.
34. Jørgensen J T. The role of biomarkers in the targeted drug development process. Invited speaker at the BDA Meeting on Developing Targeted Cancer Therapies. Royal College of Physicians, London, UK, July 3-4, 2006.

35. Jørgensen JT. Developing Molecular Diagnostics for Cancer. Invited speaker at the 14th International Tri-Conference on Molecular Medicine. Moscone Convention Center; San Francisco, CA, USA, February 27 – March 2, 2007.
36. Hoff KD, Jørgensen JT, Müller S, Rasmussen OF, Schönau A. High agreement between FISH and CISH based testing for *HER2* and *TOP2A* gene amplification. 3rd Intercontinental Congress of Pathology, Barcelona, Spain, May 17-22, 2008.
37. Jørgensen JT. Personalized Medicine – a Paradigm Shift in the Treatment of Cancer. Invited speaker at the Ehrlich II 2nd World Conference on Magic Bullets. Celebrating the 100th Anniversary of the Nobel Prize to Paul Ehrlich. Nürnberg, Germany, October 3-5, 2008.
38. Jørgensen JT. Personalized Medicine – What will the future bring? Pharmadanmark Meeting, Copenhagen, Denmark, January 28, 2009.
39. Jørgensen JT. From Blockbuster Medicine to Personalized Medicine. Invited speaker chairman at the 16th International Tri-Conference on Molecular Medicine. Moscone Convention Center; San Francisco, CA, USA, February 25 – 27, 2009.
40. Jørgensen JT. A model for drug-diagnostic co-development – Trastuzumab (Herceptin) and HercepTest. Invited speaker at the 4th Danish Conference on Biotechnology and Molecular Biology. Munkebjerg, Vejle, Denmark, May 28-29, 2009.
41. Jørgensen JT. Development of Personalized Medicine. Invited speaker at the annual meeting for the Biomedical Research Ethics Committees in Denmark. Comwell Kellers Park, Børkop, Denmark, September 24-25, 2009.
42. Jørgensen JT. Personalized Medicine – The future individualized pharmacotherapy. Invited speaker at Symposium for Biotech Research, SBR 2009. Technical University of Denmark - DTU, Lyngby, Denmark, November 11, 2009.

Books Chapters

1. Jørgensen JT. Pharmacodiagnosics and Personalized Medicine in Cancer. In: Molecular Diagnostics – The Key Driver of Personalized Cancer Medicine. Jørgensen JT and Winther H eds. World Scientific/Pan Stanford Publishing. The book will be published in 2010.
2. Jørgensen JT, Winther H. The HercepTest - From Bench to Bedside. In: Molecular Diagnostics – The Key Driver of Personalized Cancer Medicine. Jørgensen JT and Winther H eds. World Scientific/Pan Stanford Publishing. The book will be published in 2010.
3. Winther H, Jørgensen JT. Developing Molecular Diagnostics for Cancer. In: Molecular Diagnostics – The Key Driver of Personalized Cancer Medicine. Jørgensen JT and Winther H eds. World Scientific/Pan Stanford Publishing. The book will be published in 2010.

Other Publications and Presentations

1. Rasmussen M, Christrup LL, Rømsing J, Jørgensen J T, Kart T. Nye Lægemiddelformer - Smertebehandling af børn. *Farmaceuten* 1992, 22: 608-610.
2. Jørgensen JT. Syge Køer. *Samvirke* 1995; 8: 83.
3. Jørgensen JT. Klinisk videreuddannelse af farmaceuter. *Farmaceuten* 1997; 2: 51.
4. Jørgensen JT. Optimering af patientcompliance: En mulighed for at spare penge i sundhedsvæsnet. *Farmaceuten* 1998; 7: 194-195.
5. Rømsing J, Jørgensen JT, Nielsen ID. Manged Care. Fokus på patienten og tættere samarbejde i sundhedsvæsnet. *Farmaceuten* 1998; 21: 620-621.
6. Jørgensen JT. Den kliniske farmaceut i industrien. Debatmøde om kliniske farmaceuter i industrien. Sektion for Klinisk Farmaci. København, 25. april 2001.
7. Jørgensen JT. Farmakodiagnostik – et nyt redskab i den rationelle farmakoterapi ved behandling af brystkræft. *Farmaceuten* 2006, 9: 16-20.
8. Jørgensen JT. Skræddersyet medicin – ”Personalized Medicine”. *Pharma*, juli 2007: 22-27.
(http://www.pharmadanmark.dk/publicfiles/6_publicationer/pharma/juli/artikler/Pharma%20juli%2007_22-27.pdf)
9. Jørgensen JT. Fra ”Blockbuster medicine” til ”Personalized Medicine”. *Pharma*, november 2007: 24-27.
(http://www.pharmadanmark.dk/publicfiles/6_publicationer/pharma/november/artikler/Blockbuster_medicine.pdf)
10. Jørgensen JT. Hvordan virker de skræddersyede behandlinger? – Skræddersyet behandling – en revolution i sygdomsbehandlingen. Press seminar arranged by Roche Pharmaceutical. Copenhagen, March 14, 2008.
(<http://www.roche.dk/portal/synergy/static/file/synergy/alfproxy/download/1414-38d97092ccf911dd87fca15566a3509d/last/p&d+no.+5+december+2007.pdf>)
11. Jørgensen JT. Pharmacodiagnostic and Rational Drug Development. Cambridge Healthtech Institute. October 2008.
(<http://www.pharmacogenomicsnow.com/pdf/080915-Companion%20Diagnostics%20and%20Rational%20Drug%20Development.pdf>)
12. Jørgensen JT. Medicin skal målrettes patienterne. *Altinget – Sundhed*. November 25, 2008. (<http://www.altinget.dk/Sundhed/artikel.aspx?id=86842>)
13. Jørgensen JT, Rudbeck L. Pharmacodiagnostic and Personalized Medicine. *Connection* December 2008, Volume 12: 31-38. (http://pri.dako.com/28827_connection_vol12.pdf)

14. Jørgensen JT. Er blockbuster lægemidlernes tidsalder ved at være slut? - Fremtidens lægemiddelbehandling bliver mere individuel. Lif Nyheder, Medicin og Meninger, 4. december, 2008 (<http://www.lifdk.dk/sw39836.asp>)
15. Jørgensen JT. Ti år med "Personalized medicine" – hvad nu. Pharma, maj 2009:28-30. (http://www.pharmadanmark.dk/publicfiles/6_publicationer/pharma/pharma09/maj/artikler/s28-30_Personalized_medicine.pdf)
16. Jørgensen JT. A Novel Non-Gadolinium Based Oral Contrast Agent for Liver MRI. CMC Contrast News. May 12, 2009. (http://www.cmc-contrast.se/news_and_industry_trends/blog_archive/non_gadolinium_based_contrast)
17. Jørgensen JT. Skræddersyet medicin - Fremtidens individualiserede lægemiddelbehandling. Sygeplejersken September 2009; 19: 47 (<http://www.sygeplejersken.dk/sygeplejersken/default.asp?intArticleID=18675&menu=195009>)

Acknowledgements

1. Møller U. Diurnal Rhythmicity used in Experimental Cancer Research. University of Copenhagen 1985. Doctoral thesis.
2. Bech P, Haaber A, Joyce CRB: Experiments on Clinical Observation and Judgment in the Assessment of Depression: Profiled Videotapes and Judgment Analysis. *Psych Med* 1986; 873-883.
3. Kromann-Andersen B et al. Akutte nyre/ureterstenssmerter behandlet med Voltaren eller Ketogan intramuskulært. *Ugeskr Lægr* 1987; 149: 33324-6
4. Jørgensen JOL. Human Growth Hormone Replacement Therapy: Pharmacological and Clinical Aspects. University of Aarhus 1991. Doctoral thesis
5. Laursen T. Different modes of Growth Hormone Administration. Short-Term Studies in Growth Hormone Deficient Patients. University of Aarhus 1991. Ph.D. thesis.
6. Rasmussen LH. Evaluation of Recombinant Human Growth Hormone for Wound Management. Lægeforeningens Forlag. Copenhagen 1995. Doctoral thesis.
7. Mortensen M W. Design, Synthesis and Characterization of Born Containing Nanoparticles for T Cell Guided Therapy. University of Copenhagen 2005. Ph.D. thesis.

Patents

1. Jørgensen JT, Hyldstrup L, Rosholm A. Method and Apparatus for Selection and Evaluation of Substances in Treatment of Bone Disorders. Publication Date: 30.11.2000. Pub. No. WO/2000/072216.
2. Mortensen MW, Sørensen PG, Jørgensen JT, Gundersen HJG, Bjørnholm T. Boron Containing Nanoparticles Targeted to T-cells. Publication Date: 13.10.2005. Pub. No. WO/2000/072216.
3. Jørgensen JT, Ejlertsen B, Mouridsen HT, Nielsen KV. Method for Performing Prognosis for High-Risk Breast Cancer Patients using *TOP2A* Gene Aberrations. Publication Date: 10.11.2007. Pub. No. WO/2007/112746.

Memberships of Professional Societies

The Danish Society of Clinical Pharmacy

The European Society of Clinical Pharmacy

The Society for Translational Oncology

The Danish Society of Good Clinical Practice

The Danish Society of Pharmacy

The Drug Information Association

The Growth Hormone Research Society

Other Assignments

Course manager for Interpretation of Clinical Biochemistry Data, Pharmaceutical Postgraduate Education, Hillerød, Denmark, October 9 - 10, 1995

Course manager for the Clinical Pharmaceutical Postgraduate Education, Oncology. The Danish Society of Clinical Pharmacy, Copenhagen, November 21 - 23, 1996

Member of the Scientific Advisory board at The Danish Pain Research Center, Aarhus University, Aarhus, Denmark, 1997-1998

Member of the Organizing Committee for the symposium on Managed Care organized by the Danish Society of Clinical Pharmacy at Herlev Country Hospital, September 10, 1998.

Vice-president of the Danish Society of Clinical Pharmacy 1994-2000.

Referee for the Annals of Pharmacotherapy

Referee for the Journal of Pharmacy Technology

Referee for Drug Discovery Today

Referee for Personalized Medicine

Advisor to Gerson Lehrman Group Inc, New York (Healthcare & Biomedical Research)

Member of the Program Committee for the Third Alpine Meeting on Development Strategies for Next-Generation Oncology Drugs. March 14-16, 2007, Innsbruck, Austria.

Member of the BDA Working Group on Development of Targeted Cancer Therapies, 2006-2008

Member of the DK2FISH Research Group under the Danish Breast Cancer Cooperative Group, 2006-2008

Chairman on a session entitled "Incorporating Companion Diagnostics into Drug Development". 16th International Tri-Conference on Molecular Medicine. Moscone Convention Center; San Francisco, CA, February 25 – 27, 2009.

Guest Lecturer at the Department of Pharmacology and Pharmacotherapy, Faculty of Pharmaceutical Sciences, University of Copenhagen, 2009 -

Editor on "Molecular Diagnostics – The Key Driver of Personalized Cancer Medicine". Jørgensen JT and Winther H eds. World Scientific/Pan Stanford Publishing. The book will be published in 2010. (<http://www.worldscibooks.com/nanosci/v024.html>) (<http://www.panstanford.com/books/nanosci/v024.html>)